Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2019 - 2023)

Zentalis Pharmaceuticals' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $756000.0 for Q1 2023.

• In Q1 2023, Non-Current Deferred Tax Liability fell 51.16% year-over-year to $756000.0; the TTM figure through Mar 2023 stood at $756000.0 (down 51.16% YoY), while the FY2022 annual figure was $853000.0, down 95.54% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2023 stood at $756000.0, down from $853000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $19.1 million in Q4 2021, with the low at $756000.0 in Q1 2023.
• The 5-year median for Non-Current Deferred Tax Liability is $2.5 million (2019), against an average of $3.1 million.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability surged 671.77% in 2021, then tumbled 95.54% in 2022.
• Zentalis Pharmaceuticals' Non-Current Deferred Tax Liability stood at $2.5 million in 2019, then advanced by 0.69% to $2.5 million in 2020, then soared by 671.77% to $19.1 million in 2021, then sank by 95.54% to $853000.0 in 2022, then fell by 11.37% to $756000.0 in 2023.
• Business Quant data shows ZNTL's Non-Current Deferred Tax Liability at $756000.0 in Q1 2023, $853000.0 in Q4 2022, and $1.2 million in Q3 2022.